Innocoll, Inc. Provides Update of Regulatory and Partnering Activities for CollaGUARD(R) Adhesion Barrier and Launches New Product Website

Published: Apr 03, 2012

ASHBURN, Va., April 3, 2012 /PRNewswire/ Innocoll Inc. announces that its distribution network for CollaGUARD has now been expanded to cover 34 countries including Europe, China, SE Asia, Canada and the Middle East. The Company expects to have partnered CollaGUARD in 75 countries by the end of 2012, including the US and Japan, which are major markets for adhesion barrier products.

In addition to recent approvals in the EU and other territories, Innocoll has also submitted filings in Canada, Australia, and India. In the second and third quarter of this year, Innocoll anticipates filing CollaGUARD in additional countries and regions including: Russia, Korea, Israel, SE Asia, the Gulf States, Brazil and Mexico.

Innocoll is pleased to announce that the company has launched a dedicated product website for CollaGUARD as a resource for our partners and users of the product. The site is available in four different languages and can be accessed at

Dr. Michael Myers, President and CEO stated, "We are very pleased with the progress made with CollaGUARD to date and we are very committed to providing resources and tools that support our partners marketing efforts."

About CollaGUARD®
CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions and may be used in patients undergoing laparotomy or laparoscopic surgeries. When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (P < 0.001) and significantly reduced the extent and severity of adhesions (P < 0.001).

CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and antiadhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 30 x 20cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries.

For more information please visit

About Postoperative Adhesions
Postoperative adhesions are abnormal fibrous connections that can form between any apposing internal organ and serous membraneas a natural consequence of abdominopelvic surgery. Adhesions occur in almost 95% of laparotomies and may lead to serious complications such as intestinal obstruction, secondary female infertility, and chronic abdominal or pelvic pain. More than 30% of patients who undergo open gynecologic or general surgery are readmitted within 10 years for disorders that are considered directly or potentially related to adhesions, with an average of 2 readmissions per patient. In the United States, there are approximately 350,000 hospitalizations annually for adhesiolysis following gynecologic or abdominal surgery, which account for almost 1 million inpatient days at a cost of $2.3 billion. Even for patients without complications, adhesions originating from a previous surgery can present significant surgical challenges and additional morbidity risks in subsequent operations.

About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil, CollaPress and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD, Collieva®, CollaCare®, Collexa®, Zorpreva, and LidoColl®.

Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and XaraColl in phase 3 for the management of post-operative pain. For more information, please visit

SOURCE Innocoll, Inc.

Back to news